Bio-Fd&C
바이오에프디엔씨 · 251120
Health Care Pharmaceuticals · KOSDAQ
Market cap US$62.2M (₩85.8B)
Overview
Bio-Fd&C develops and produces active ingredients derived from plant cells, including growth factors, peptides, and cell lines, used as raw materials in cosmetics, dietary supplements, and pharmaceuticals.
Listed on KOSDAQ, Korea's tech and small-cap board, it supplies these plant-cell-derived materials to cosmetics and life-science companies in Korea and internationally. Its core business rests on a proprietary plant-cell cultivation platform, and plant-cell-derived active ingredients are its primary revenue-generating product line.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$11.3M
- FY2024US$11.6M
- FY2025US$13.9M
Operating profit
- FY2023US$3.6M
- FY2024US$3.5M
- FY2025US$4.5M
Net income
- FY2023US$4M
- FY2024US$3.3M
- FY2025US$4.8M
Key ratios (FY2025)
Why it matters
The company supplies cell lines to named international customers including Switzerland-based Givaudan, giving it a cross-border supply-chain role unusual for a KOSDAQ small-cap.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?